|Other Names||Midkine, MK, Amphiregulin-associated protein, ARAP, Midgestation and kidney protein, Neurite outgrowth-promoting factor 2, Neurite outgrowth-promoting protein, MDK, MK1, NEGF2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7781a was selected from the N-term region of human MDK. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Developmentally regulated, secreted growth factor homologous to pleiotrophin (PTN), which has heparin binding activity. Binds anaplastic lymphoma kinase (ALK) which induces ALK activation and subsequent phosphorylation of the insulin receptor substrate (IRS1), followed by the activation of mitogen-activated protein kinase (MAPK) and PI3-kinase, and the induction of cell proliferation. Involved in neointima formation after arterial injury, possibly by mediating leukocyte recruitment. Also involved in early fetal adrenal gland development (By similarity).|
|Tissue Location||Expressed in various tumor cell lines. In insulinoma tissue predominantly expressed in precancerous lesions|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
MDK has heparin binding activity and growth promoting activity. It is involved in neointima formation after arterial injury, possibly by mediating leukocyte recruitment and also involved in early fetal adrenal gland development.
Huang,Y., Biochem. Biophys. Res. Commun. 377 (2), 474-478 (2008)Ikematsu,S., Cancer Sci. 99 (10), 2070-2074 (2008)Ota,K., Br. J. Cancer 99 (4), 655-662 (2008)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.